The testicular-derived Sertoli cell: cellular immunoscience to enable transplantation.
There is a renewed enthusiasm for the potential of cellular transplantation as a therapy for numerous clinical disorders. The revived interest is largely due to the unprecedented success of the "Edmonton protocol," which produced a 100% cure rate for type I diabetics following the transplantation of human islet allografts together with a modified immunosuppressive regimen. While these data provide a clear and unequivocal demonstration that transplantation is a viable treatment strategy, the shortage of suitable donor tissue together with the debilitating consequences of lifelong immunosuppression necessitate a concerted effort to develop novel means to enable transplantation on a widespread basis. This review outlines the use of Sertoli cells to provide local immunoprotection to cografted discordant cells, including those from xenogeneic sources. Sertoli cells are normally found in the testes where one of their functions is to provide local immunologic protection to developing germ cells. Isolated Sertoli cells 1) engraft and self-protect when transplanted into allogeneic and xenogeneic environments, 2) protect cografted allogeneic and xenogeneic cells from immune destruction, 3) protect islet grafts to reverse diabetes in animal models, 4) enable survival and function of cografted foreign dopaminergic neurons in rodent models of Parkinson's disease (PD), and 5) promote regeneration of damaged striatal dopaminergic circuitry in those same PD models. These benefits are discussed in the context of several potential underlying biological mechanisms. While the majority of work to date has focused on Sertoli cells to facilitate transplantation for diabetes and PD, the generalized ability of these unique cells to potently suppress the local immune environment opens additional clinical possibilities.
Emerich
Dwaine F
DF
Sertoli Technologies, Inc, Cranston RI 02921, USA. ED3FJM@aol.com
Hemendinger
Richelle
R
Halberstadt
Craig R
CR
D000818:Animals; D003920:Diabetes Mellitus / Q000628:therapy; D004195:Disease Models, Animal; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods* / Q000639:trends*; D008297:Male; D010300:Parkinson Disease / Q000628:therapy; D012708:Sertoli Cells / Q000276:immunology / Q000637:transplantation*; D016378:Tissue Transplantation / Q000379:methods* / Q000639:trends*; D023001:Transplantation Tolerance / Q000276:immunology; D014183:Transplantation, Heterologous / Q000276:immunology